Critical Reviews in Clinical Laboratory Sciences

(The TQCC of Critical Reviews in Clinical Laboratory Sciences is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
The COVID-19 pandemic777
Biomarkers associated with COVID-19 disease progression537
COVID-19: from an acute to chronic disease? Potential long-term health consequences221
Current concepts and advances in biomarkers of acute kidney injury83
The COVID-19 pandemic: viral variants and vaccine efficacy67
Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review59
Vitamin B12status in health and disease: a critical review. Diagnosis of deficiency and insufficiency – clinical and laboratory pitfalls59
Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites57
Potential value and impact of data mining and machine learning in clinical diagnostics54
A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients51
Molecular diagnostic assays for COVID-19: an overview47
The laboratory’s role in combating COVID-1936
Recent evolutions of machine learning applications in clinical laboratory medicine26
The molecular structure and biological functions of RNA methylation, with special emphasis on the roles of RNA methylation in autoimmune diseases24
Molecular tissue profiling by MALDI imaging: recent progress and applications in cancer research23
Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath23
The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome23
Implementation of patient-based real-time quality control22
What the lab can and cannot do: clinical interpretation of drug testing results20
Nucleic acid-based electrochemical biosensors for rapid clinical diagnosis: advances, challenges, and opportunities20
Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-1920
Liquid biopsy with cell free DNA: new horizons for prostate cancer18
T helper cells in depression: central role of Th17 cells18
The potential impact of salivary peptides in periodontitis18
Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future17
Oligoclonal bands: clinical utility and interpretation cues17
The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets16
Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology15
Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis15
CRISPR-based biosensing systems: a way to rapidly diagnose COVID-1915
Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS)15
Identifying and overcoming barriers to harmonize newborn screening programs through consensus strategies14
Smartphone technology facilitates point-of-care nucleic acid diagnosis: a beginner’s guide13
DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing13
Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer13